Literature DB >> 2042444

Acute transformation in nonleukemic chronic myeloproliferative disorders: actuarial probability and main characteristics in a series of 218 patients.

F Cervantes1, D Tassies, C Salgado, M Rovira, A Pereira, C Rozman.   

Abstract

In a series of 218 subjects diagnosed as having nonleukemic chronic myeloproliferative disorders in a single institution within a 18-year period, 13 instances of acute transformation were registered. They corresponded to 8 out of 70 patients with idiopathic myelofibrosis (IM), 4 out of 91 with polycythemia vera (PV), and 1 out of 57 with essential thrombocythemia (ET). The actuarial probability of developing such a complication at 100 months from diagnosis reached 20.6% in IM, 8.7% in PV, and 4% in ET. Only 1 IM patient whose condition developed into acute leukemia had received prior cytolytic therapy, whereas, in contrast, all PV and ET patients showing this pattern had previously been treated with either 32P or alkylating agents. On the other hand, acute transformation in IM generally had an insidious presentation, contrasting with its abrupt onset in most PV and ET patients. Most acute leukemias (12 out of 13) exhibited a myeloid phenotype. The patients' median survival from diagnosis of the acute transformation was only 3 months, the development of this complication significantly shortening the patients' overall survival.

Entities:  

Mesh:

Year:  1991        PMID: 2042444     DOI: 10.1159/000204873

Source DB:  PubMed          Journal:  Acta Haematol        ISSN: 0001-5792            Impact factor:   2.195


  42 in total

Review 1.  Myeloid blastic transformation of myeloproliferative neoplasms--a review of 112 cases.

Authors:  Syed J Noor; Wei Tan; Gregory E Wilding; Laurie A Ford; Maurice Barcos; Sheila N J Sait; Annemarie W Block; James E Thompson; Eunice S Wang; Meir Wetzler
Journal:  Leuk Res       Date:  2010-08-19       Impact factor: 3.156

2.  Risk of disease transformation and second primary solid tumors in patients with myeloproliferative neoplasms.

Authors:  Junshik Hong; Ju Hyun Lee; Ja Min Byun; Ji Yun Lee; Youngil Koh; Dong-Yeop Shin; Jeong-Ok Lee; Sang Mee Hwang; Hyoung Soo Choi; Inho Kim; Sung-Soo Yoon; Soo-Mee Bang
Journal:  Blood Adv       Date:  2019-11-26

3.  Safety and efficacy of combined ruxolitinib and decitabine in accelerated and blast-phase myeloproliferative neoplasms.

Authors:  Raajit K Rampal; John O Mascarenhas; Heidi E Kosiorek; Leah Price; Dmitriy Berenzon; Elizabeth Hexner; Camille N Abboud; Marina Kremyanskaya; Rona Singer Weinberg; Mohamed E Salama; Kamal Menghrajani; Vesna Najfeld; Lonette Sandy; Mark L Heaney; Ross L Levine; Ruben A Mesa; Amylou C Dueck; Judith D Goldberg; Ronald Hoffman
Journal:  Blood Adv       Date:  2018-12-26

Review 4.  Role of hematopoietic stem cell transplantation in patients with myeloproliferative disease.

Authors:  Rachel B Salit; H Joachim Deeg
Journal:  Hematol Oncol Clin North Am       Date:  2014-10-03       Impact factor: 3.722

5.  Genomic analysis of myeloproliferative neoplasms in chronic and acute phases.

Authors:  Frédéric Courtier; Nadine Carbuccia; Séverine Garnier; Arnaud Guille; José Adélaïde; Nathalie Cervera; Véronique Gelsi-Boyer; Marie-Joelle Mozziconacci; Jérôme Rey; Norbert Vey; Max Chaffanet; Daniel Birnbaum; Anne Murati
Journal:  Haematologica       Date:  2016-10-14       Impact factor: 9.941

6.  JARID2 Functions as a Tumor Suppressor in Myeloid Neoplasms by Repressing Self-Renewal in Hematopoietic Progenitor Cells.

Authors:  Hamza Celik; Won Kyun Koh; Ashley C Kramer; Elizabeth L Ostrander; Cates Mallaney; Daniel A C Fisher; Jingyu Xiang; William C Wilson; Andrew Martens; Alok Kothari; Gregory Fishberger; Eric Tycksen; Darja Karpova; Eric J Duncavage; Youngsook Lee; Stephen T Oh; Grant A Challen
Journal:  Cancer Cell       Date:  2018-11-12       Impact factor: 31.743

Review 7.  Underlying mechanisms of the JAK2V617F mutation in the pathogenesis of myeloproliferative neoplasms.

Authors:  A Mullally
Journal:  Pathologe       Date:  2016-11       Impact factor: 1.011

8.  Allogeneic stem cell transplantation for myelofibrosis with leukemic transformation.

Authors:  Stefan O Ciurea; Marcos de Lima; Sergio Giralt; Rima Saliba; Carlos Bueso-Ramos; Borje S Andersson; Chitra M Hosing; Srdan Verstovsek; Richard E Champlin; Uday Popat
Journal:  Biol Blood Marrow Transplant       Date:  2010-01-29       Impact factor: 5.742

9.  The natural history and treatment outcome of blast phase BCR-ABL- myeloproliferative neoplasms.

Authors:  Constantine S Tam; Roberto M Nussenzveig; Uday Popat; Carlos E Bueso-Ramos; Deborah A Thomas; Jorge A Cortes; Richard E Champlin; Stefan E Ciurea; Taghi Manshouri; Sherry M Pierce; Hagop M Kantarjian; Srdan Verstovsek
Journal:  Blood       Date:  2008-06-19       Impact factor: 22.113

Review 10.  Leukemic Transformation of Myeloproliferative Neoplasms: Therapeutic and Genomic Considerations.

Authors:  Bing Li; John O Mascarenhas; Raajit K Rampal
Journal:  Curr Hematol Malig Rep       Date:  2018-12       Impact factor: 3.952

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.